Original Publication Date: 1 June, 2014
Publication / Source: Clinical Investigation
Authors: Dai Chu Luu, Joseph Chao
The scope of the problem: defining resistance to angiogenesis inhibitors
Angiogenesis is well recognized as an important process in tumor growth and progression. It can be an extremely complex process, although the preponderance of drivers and mediators permits opportunities in drug development to inhibit this process. Key signaling molecules in angiogenesis include the VEGF, FGF2, angiopoietins 1 and 2, HGF and ephrin . The prototypical example of an angiogenesis inhibitor in routine clinical use is bevacizumab, a first-generation recombinant humanized monoclonal antibody against VEGF-A .